<DOC>
	<DOCNO>NCT02055287</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetics ( PK ) LY03004 follow escalate single intramuscular injection 12.5 , 25 , 37.5 , 50 mg ; evaluate safety tolerability preliminary efficacy LY03004 follow intramuscular injection .</brief_summary>
	<brief_title>Pharmacokinetic Safety Study LY03004 Stable Patients With Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>1 . Male female patient age 18 65 year old ; 2 . Patients must DSMIV diagnosis schizophrenia schizoaffective disorder base MiniInternational Neuropsychiatric Interview ( MINI ) ; 3 . Patients must clinically stable antipsychotic medication risperidone paliperidone clozapine least 4 week prior screen , base clinical assessment Positive Negative Syndrome Scale ( PANSS ) total score less equal 70 screen visit ; 4 . Patients Body Mass Index range 18.0 35.0 ; 5 . Patients Informed consent form sign patient legally acceptable representative 1 . Patients mental disorder schizophrenia schizoaffective disorder , accord DSMIV ; 2 . Patients receive oral risperidone paliperidone clozapine within 14 day prior screen , Risperdal Consta within 100 day prior screen paliperidone palmitate within 10 month prior screen ; 3 . Patients neuroleptic malignant syndrome physical fatigue associate dehydration malnutrition ; 4 . Patients pose significant risk suicide attempt base history , investigator 's judgment answer `` yes '' question 4 5 current past 30 day screen form Columbia Suicide Severity Rating Scale ( CSSRS ) . 5 . Patients history sensitivity akathisia EPS , especially previous use risperidone paliperidone . 6 . Patients uncontrolled diabetes mellitus indicate HbA1c level great equal 7 % ; 7 . Patients history currently epilepsy convulsion disorder ; 8 . Patients electroconvulsive therapy within past 2 month prior screen ; 9 . Patients used medication know inducer inhibitor CYP 2D6 less 2 week prior screen ; 10 . Patients history allergic reaction risperidone excipients LY03004 ; 11 . Patients meet DSMIVTR criterion substance abuse dependence exception caffeine nicotine past 6 month prior screen 12 . Patients history clinically relevant cardiac arrhythmia 's , cardiovascular disease , thyrotoxicosis , parkinsonism , hemorrhagic diathesis ; 13 . Patients currently take medication primarily CNS activity antidepressant , mood stabilizer anticonvulsant ; 14 . Patients participate clinical trial another investigational drug within 30 day prior screen ; 15 . Female patient pregnant breastfeed childbearing potential without adequate contraception . 16 . Patients clinically relevant hepatic , renal cardiac dysfunction , medical condition laboratory abnormality , judgment investigator would interfere subject 's ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective disorder</keyword>
</DOC>